Affiliation:
1. Antibiotic Discovery and Development, Merck Research Laboratories, Rahway, New Jersey 07065-0900, USA. george_abruzzo@merck.com
Abstract
The in vivo activity of the Merck antifungal echinocandin drug candidate MK-0991 (L-743,872) was evaluated in mouse models of disseminated candidiasis, aspergillosis, and cryptococcosis. The echinocandins are potent inhibitors of 1,3-beta-D-glucan synthase. Two models of disseminated candidiasis were used. In a Candida albicans mouse survival model with both DBA/2N and CD-1 mice, estimates of the 50% effective doses (ED50s) of MK-0991 were 0.04 and 0.10 mg/kg of body weight/dose at 21 days after challenge, respectively. In a C. albicans target organ assay (TOA) with DBA/2N mice, MK-0991 at levels of > or =0.09 mg/kg/dose significantly reduced the numbers of C. albicans CFU/g of kidneys compared to the numbers in the kidneys of control mice from 1 to 28 days after challenge. Even when given as a single intraperitoneal dose either 30 min or 24 h after challenge, MK-0991 was effective and significantly reduced the numbers of C. albicans CFU/g of kidney compared to those in the controls. MK-0991 was >300-fold less active when it was administered orally than when it was administered parenterally. MK-0991 was efficacious in mouse TOAs against other C. albicans strains and Candida species including Candida tropicalis, Candida (Torulopsis) glabrata, Candida lusitaniae, Candida parapsilosis, and Candida krusei. MK-0991 was ineffective against disseminated Cryptococcus neoformans infections. In the model of disseminated aspergillosis in mice, MK-0991 at doses of > or =0.02 mg/kg/dose significantly prolonged the survival of DBA/2N mice, with estimates of the ED50 and ED90 of MK-0991 being 0.03 and 0.12 mg/kg/dose, respectively, at 28 days after challenge. MK-0991 is a potent, parenterally administered therapeutic agent against disseminated candidiasis and aspergillosis that warrants further investigation in human clinical trials.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference40 articles.
1. Evaluation of water soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of aspergillosis, candidiasis, and cryptococcosis;Abruzzo G. K.;Antimicrob. Agents Chemother.,1995
2. Abruzzo G. K. A. M. Flattery C. J. Gill L. Kong J. G. Smith V. B. Pikounis H. Kropp H. Rosen and K. Bartizal. 1996. Evaluation of water soluble pneumocandin L-743 872 in mouse models of disseminated aspergillosis candidiasis and cryptococcosis abstr. F37 p. 106. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C.
3. Abruzzo G. K. A. Flattery C. Gill J. Smith H. Kropp and K. Bartizal. 1993. Evaluation of water soluble lipopeptides in a mouse model of disseminated aspergillosis abstr. 355 p. 184. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C.
4. Pneumocandin antifungal lipopeptides. The phenolic hydroxyl is required for 1,3-~-D-glucan synthesis inhibition;Balkovec J. M.;Bioorg. Med. Chem. Lett.,1993
5. Bartizal K. G. Abruzzo and D. Schmatz. 1993. The pneumocandins: biological activity of the pneumocandins p. 421-455. In J. Rippon and R. A. Fromtling (ed.) Cutaneous fungal infections. Marcel Dekker Inc. New York N.Y.
Cited by
227 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献